ClinicalTrials.gg
CompletedNCT02865538RELENT-1Updated Feb 7, 2025Results posted

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

A Phase 1/2 interventional study of BAY3427080 and Placebo (for BAY3427080) in Post-menopausal Vasomotor Symptoms, sponsored by Bayer. Completed at 3 sites in United States. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Bayer · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
6th of 13
76 · median 64
Started
2016
the only one that year
Phase 1/2
Only one
of the 13
Registered
1st of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 6th largest by enrollment, is the only one that started in 2016, is the only one in phase 1/2, and was the 1st registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 45 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.

03

Conditions studied

  • Post-menopausal Vasomotor Symptoms

Browse trials for

Keywords

  • Hot flashes
  • Post-menopausal
04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female subjects experiencing frequent moderate to severe hot flashes.Menopause will be defined as:

    • 12 months of spontaneous amenorrhea;
    • OR at least 6 weeks' post-surgical bilateral oophorectomy with or without hysterectomy.

Exclusion criteria

Exclusion Criteria:

  • > 35kg/m2.
  • Any active comorbid disease, or laboratory result deemed by the investigator to be and which could impact safety during study conduct or that could interfere with the study evaluation, procedures or completion.
  • Use of prohibited medications defined in the protocol.
  • Inability or unwillingness to comply with study procedures or requirements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Placebo comparator
    BAY3427080 Placebo

    Drug: Placebo (for BAY3427080)

  • Experimental
    50mg BAY3427080

    Drug: BAY3427080

  • Experimental
    100mg BAY3427080

    Drug: BAY3427080

  • Experimental
    150mg BAY3427080

    Drug: BAY3427080

  • Experimental
    300mg BAY3427080

    Drug: BAY3427080

Interventions

  • Also known as: NT-814

  • DrugPlacebo (for BAY3427080)
06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of BAY3427080

    Cmax is the maximum observed plasma concentration of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.

    Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)

  2. Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of BAY3427080

    Time of occurrence of Cmax.Time to reach maximum plasma concentration of BAY3427080 was presented. Blood samples for Tmax were taken within 30 minutes prior to dose administration.

    Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)

  3. Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080

    AUC from time zero extrapolated to infinity of BAY3427080 was presented. AUC0-∞ was only estimated following the Day 1 dose.

    Time frame: Day 1 (pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours)

  4. Area Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-τ) of BAY3427080

    Area under the concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration of BAY3427080 was presented. Blood samples for (AUC0-τ) were taken within 30 minutes prior to dose administration.

    Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)

  5. Terminal Elimination Half-life (t½) of BAY3427080

    Terminal elimination half-life of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.

    Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)

  6. Apparent Clearance (CL/F) of BAY3427080

    Apparent clearance of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.

    Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)

  7. Number of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination.

    A physician or appropriately qualified delegate conducted a full physical examination. Clinically significance was decided by investigator. The findings are presented as abnormal (clinically significant).

    Time frame: At day 14

  8. Number of Participants With Clinically Significant Abnormalities on the 12-lead ECGs

    Reported results are cardiovascular system-examination findings at day 14. Clinically significance was decided by investigator. The findings are presented as abnormal (clinically significant).

    Time frame: At day 14

  9. Number of Participants With Arrhythmias as Assessed by Continuous Holter Monitoring.

    Holter monitors were supplied by iCardiac Technologies. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14 and remained in place until 24-hour assessments were completed.

    Time frame: Baseline (day -1) and day 14

  10. Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Standing)

    Diastolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in standing position.

    Time frame: Baseline and day 14

  11. Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Sitting)

    Diastolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in sitting position.

    Time frame: Baseline and day 14

  12. Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Standing)

    Systolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in standing position.

    Time frame: Baseline and day 14

  13. Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Sitting)

    Systolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in sitting position.

    Time frame: Baseline and day 14

  14. Change From Baseline at Day 14 in Vital Signs: Pulse Rate

    Pulse rate was measured just prior to dosing (approx. 30 mins).

    Time frame: Baseline and day 14

  15. Change From Baseline at Day 14 in Vital Signs: Respiratory Rate

    Respiratory rate was measured just prior to dosing (approx. 30 mins).

    Time frame: Baseline and day 14

  16. Change From Baseline at Day 14 in Vital Signs: Oxygen Saturation

    Oxygen Saturation was measured just prior to dosing (approx. 30 mins).

    Time frame: Baseline and day 14

  17. Change From Baseline at Day 14 in Vital Signs: Oral Body Temperature

    Temperature was measured just prior to dosing (approx. 30 mins).

    Time frame: Baseline and day 14

  18. Change From Baseline at Day 14 in Vital Signs: Weight

    Weight was measured just prior to dosing (approx. 30 mins).

    Time frame: Baseline and day 14

  19. Change From Baseline at Day 15 for Laboratory Hormones Results : Adrenocorticotropic Hormone (ADTH) and Estradiol.

    Blood samples for the assessment of ACTH and Estradiol were collected upon participants admission to the unit.

    Time frame: Baseline and day 15

  20. Change From Baseline at Day 15 for Laboratory Hormones Results: Follicle Stimulating Hormone

    Blood samples for the assessment of Follicle Stimulating were collected upon participants admission to the unit.

    Time frame: Baseline and day 15

  21. Change From Baseline at Day 15 for Laboratory Hormones Results : Triiodothyronine Uptake

    Blood samples for the assessment of Triiodothyronine were collected upon participants admission to the unit.

    Time frame: Baseline and day 15

  22. Change From Baseline at Day 15 for Laboratory Hormones Results: Thyrotropin

    Blood samples for the assessment of Thyrotropin were collected upon participants admission to the unit.

    Time frame: Baseline and day 15

  23. Change From Baseline at Day 15 for Laboratory Hormones Results : Cortisol, Testosterone, Thyroxine and Triiodothyronine

    Blood samples for the assessment of Cortisol, Testosterone, Thyroxine and Triiodothyronine were collected upon participants admission to the unit.

    Time frame: Baseline and day 15

  24. Change From Baseline at Day 14 for Clinical Laboratory Parameters LIPIDS : Cholesterol, Triglycerides, HDL Cholesterol and LDL Cholesterol.

    Blood samples for the assessment of Cholesterol, Triglycerides,high-density lipoprotein (HDL)Cholesterol and low-density lipoprotein (LDL) Cholesterol were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  25. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils and Immature Granulocytes.

    Blood samples for the assessment of Neutrophils/Leukocytes, Lymphocytes /Leukocytes, Monocytes/Leukocytes, Eosinophils/Leukocytes, Basophils/Leukocytes and Immature Granulocytes/ Leukocytes were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  26. Change From Baseline at Day 14 for Clinical Laboratory Parameters HEMATOLOGY: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets.

    Blood samples for the assessment of Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets were collected upon participant's admission to the unit.

    Time frame: Baseline and day 14

  27. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin Concentration

    Blood samples for the assessment of Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HB)concentration were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  28. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes

    Blood samples for the assessment of Erythrocytes were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  29. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume.

    Blood samples for the assessment of Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  30. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples for the assessment of Erythrocytes Mean Corpuscular Hemoglobin were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  31. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Distribution Width.

    Blood samples for the assessment of Erythrocytes Distribution Width were collected upon participants admission to the unit. Erythrocytes distribution width (in percentage) = 1 SD of Erythrocyte volume/MCV x 100%

    Time frame: Baseline and day 14

  32. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hematocrit.

    Blood samples for the assessment of Hematocrit were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  33. Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Protein and Albumin.

    Blood samples for the assessment of Protein and Albumin were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  34. Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase

    Blood samples for the assessment of Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  35. Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Urate, Bilirubin and Creatinine.

    Blood samples for the assessment of Urate, Bilirubin and Creatinine were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  36. Change From Baseline at Day 14 for Clinical Laboratory Parameters CHEMISTRY: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen.

    Blood samples for the assessment of Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen were collected upon participant's admission to the unit.

    Time frame: Baseline and day 14

  37. Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at Baseline

    Blood samples for the assessment of Glomerular Filtration Rate African were collected upon participants admission to the unit.

    Time frame: At Baseline

  38. Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at Baseline

    Blood samples for the assessment of Glomerular Filtration Rate Caucasian were collected upon participants admission to the unit.

    Time frame: At Baseline

  39. Change From Baseline at Day 14 for COAGULATION: Prothrombin International Normalized Ratio (INR)

    Blood samples for the assessment of Prothrombin International Normalized Ratio were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  40. Change From Baseline at Day 14 for COAGULATION: Prothrombin Time and Activated Partial Thromboplastin Time

    Blood samples for the assessment of Prothrombin Time and Activated Partial Thromboplastin Time were collected upon participants admission to the unit.

    Time frame: Baseline and day 14

  41. Heart Rate (HR) - Change From Baseline (Day -1) at Day 14

    Heart rate was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made.Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

    Time frame: Baseline (day -1) and day 14

  42. Mean PR Interval - Change From Baseline (Day -1) at Day 14

    PR Interval was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

    Time frame: Baseline (day -1) and day 14

  43. Mean QRS Duration - Change From Baseline (Day -1) at Day 14

    QRS Duration was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

    Time frame: Baseline (day -1) and day 14

  44. Mean QT Interval - Change From Baseline (Day -1) at Day 14

    QT Interval was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

    Time frame: Baseline (day -1) and day 14

  45. Mean QTcF Interval (Fridericia's Correction Formula, QTcF) - Change From Baseline (Day -1) at Day 14

    Fridericia-corrected QTcF interval was evaluated as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

    Time frame: Baseline (day -1) and day 14

  46. Mean QTcB Interval (Bazett's Correction Formula, QTcB) - Change From Baseline (Day -1) at Day 14

    Bazett-corrected QTcB interval was evaluated as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

    Time frame: Baseline (day -1) and day 14

  47. Nature and Severity of Adverse Events (AEs) up to Day 21

    An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product. Serious Adverse Event (SAE) is an adverse event that at any dose: Results in death, Is life-threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe), Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is considered to be an important medical event.

    Time frame: On or after first drug administration up to end of study (Day 21).

  48. Withdrawals Due to AEs up to Day 21

    An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product. Serious Adverse Event (SAE) is an adverse event that at any dose: Results in death, Is life-threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe), Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is considered to be an important medical event.

    Time frame: On or after first drug administration up to end of study (Day 21)

Secondary outcomes

  1. Change in Frequency of Hot Flushes From Baseline (Day -1) at Days 7, 14 as Assessed by Skin Conductance

    Sternal skin conductance monitors (the Bahr MonitorTM) and the associated algorithm software were supplied by Simplex Scientific LLC (Middleton, USA). Participants were instructed to push a button on the skin conductance monitor when they sensed a hot flush when fitted with the monitor and then provide details of the hot flush in the continuous hot flush diary. Sternal skin conductance monitors were fitted on Day -1 (24 hours±1 hour prior to the planned study drug administration on Day 1) and remained in place until after the Day 7 24-hour assessments were completed (on Day 8). Refitted around 30 minutes prior to study drug administration on Day 14 and remained in place until after the 24-hour assessments were completed on Day 15.

    Time frame: Baseline (day -1) and days 7, 14

  2. Change From Baseline (Week -1) at Weeks 1, 2 in Frequency of Moderate to Severe Hot Flushes as Measured by Twice Daily Paper Diary Throughout Study

    Hot flush frequency and hot flush severity were obtained using the Hot Flush paper Diary. Subjects documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.

    Time frame: Baseline (week -1) and Week 1 ,Week 2

  3. Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Severity of Hot Flushes as Measured by Twice Daily Paper Diary

    Participants documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.

    Time frame: Baseline (week -1) and weeks 1, Week 2

  4. Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Hot Flushes Severity Score as Measured by Twice Daily Paper Diary.

    The hot flushes severity score was a composite of the frequency and severity of hot flushes, and was calculated as follows: number of mild hot flushes recorded on Day Y + number of moderate hot flushes recorded on Day Y × 2 + number of severe hot flushes recorded on Day Y × 3. Higher scores mean more severe hot flushes.

    Time frame: Baseline (week -1) and week 1 , 2

  5. Change in Frequency From Baseline (Day -1), at Days 7, 14 of Hot Flushes as Measured by Continuous Day Time Diary.

    Subjects recorded each hot flush and its severity on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3) in the hot flush paper diary as they occurred during the day and night.

    Time frame: Baseline(day -1) and Day 7, 14

  6. Change From Baseline (Week -1) at Weeks 1, 2 in Night-time Awakenings (NTA) Secondary to Hot Flushes as Measured by Paper Diary

    The number of NTAs secondary to hot flushes was the sum of the number of moderate and severe night-time hot flushes recorded the following morning (twice-daily hot flush diary) or recorded contemporaneously on the continuous diary.

    Time frame: Baseline (week-1) and weeks 1 , 2

  7. Change From Baseline (Day-1) to Day 1 and Day 7 in Luteinizing Hormone (AUC0-8)

    Change in Luteinizing Hormone(LH) AUC from time zero to 8 hours. Pre-dose samples for LH were taken within 30 minutes prior to dose administration.

    Time frame: baseline (day-1) to day 1 and day 7, pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours)

07

Results

Posted Feb 16, 2021

Participant flow

The study was conducted between 01 August 2016 (first subject, screening visit) and 28 March 2017 (last subject, last visit).

Participant flow — Overall Study
MilestonePlacebo Comparator50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg of BAY3427080
Started1815151513
Completed1715141513
Not completed10100
Withdrew: Withdrawal by subject00100
Withdrew: Lost to follow-up10000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of BAY3427080

Cmax is the maximum observed plasma concentration of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.

Time frame:
On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of BAY3427080
ng/mLPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day 1—502.62 ± 90.19731.69 ± 110.58911.48 ± 148.281576.01 ± 90.70
Day 7—548.60 ± 57.47809.48 ± 116.581173.50 ± 95.142045.61 ± 152.87
Day 14—522.36 ± 87.88841.42 ± 107.161188.19 ± 131.202851.83 ± 116.53
PrimaryTime to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of BAY3427080

Time of occurrence of Cmax.Time to reach maximum plasma concentration of BAY3427080 was presented. Blood samples for Tmax were taken within 30 minutes prior to dose administration.

Time frame:
On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Reported as:
Geometric mean · hr
Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of BAY3427080
hrPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day 1—1.360 ± 40.011.320 ± 38.791.521 ± 41.951.471 ± 63.05
Day 7—1.432 ± 39.251.623 ± 43.191.536 ± 40.081.754 ± 56.18
Day 14—1.265 ± 46.321.445 ± 56.711.296 ± 23.351.342 ± 33.46
PrimaryArea Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080

AUC from time zero extrapolated to infinity of BAY3427080 was presented. AUC0-∞ was only estimated following the Day 1 dose.

Time frame:
Day 1 (pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours)
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080
hr*ng/mLPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080—2018.68 ± 38.431545.58 ± 3.491151.87 ± 66.736249.52 ± 101.01
PrimaryArea Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-τ) of BAY3427080

Area under the concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration of BAY3427080 was presented. Blood samples for (AUC0-τ) were taken within 30 minutes prior to dose administration.

Time frame:
On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Reported as:
Geometric mean · hr*ng/mL
Area Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-τ) of BAY3427080
hr*ng/mLPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day 1—1400.167 ± 67.872341.882 ± 71.193012.793 ± 97.746527.569 ± 70.50
Day 7—2506.97 ± 48.054472.76 ± 63.836202.894 ± 43.9212859.660 ± 85.47
Day 14—2341.55 ± 64.733542.41 ± 86.345163.500 ± 88.7114822.860 ± 99.68
PrimaryTerminal Elimination Half-life (t½) of BAY3427080

Terminal elimination half-life of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.

Time frame:
On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Reported as:
Geometric mean · hr
Terminal Elimination Half-life (t½) of BAY3427080
hrPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day 1—2.409 ± 34.151.903 ± 11.983.965 ± 45.943.142 ± 18.92
Day 7—2.443 ± 9.333.303 ± 21.203.482 ± 22.572.271
Day 14—2.698 ± 21.642.04221.593 ± 24.5820.427 ± 22.85
PrimaryApparent Clearance (CL/F) of BAY3427080

Apparent clearance of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.

Time frame:
On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Reported as:
Geometric mean · L/hr
Apparent Clearance (CL/F) of BAY3427080
L/hrPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day 1—24.769 ± 38.4364.700 ± 3.49130.223 ± 66.7348.004 ± 101.01
Day 7—19.944 ± 48.0522.358 ± 63.8324.182 ± 43.9223.329 ± 85.47
Day 14—21.353 ± 64.7328.229 ± 86.3429.050 ± 88.7120.239 ± 99.68
PrimaryNumber of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination.

A physician or appropriately qualified delegate conducted a full physical examination. Clinically significance was decided by investigator. The findings are presented as abnormal (clinically significant).

Time frame:
At day 14
Reported as:
Number · Participants
Number of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination.
ParticipantsPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Number of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination.10212
PrimaryNumber of Participants With Clinically Significant Abnormalities on the 12-lead ECGs

Reported results are cardiovascular system-examination findings at day 14. Clinically significance was decided by investigator. The findings are presented as abnormal (clinically significant).

Time frame:
At day 14
Reported as:
Number · Participants
Number of Participants With Clinically Significant Abnormalities on the 12-lead ECGs
ParticipantsPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Number of Participants With Clinically Significant Abnormalities on the 12-lead ECGs00100
PrimaryNumber of Participants With Arrhythmias as Assessed by Continuous Holter Monitoring.

Holter monitors were supplied by iCardiac Technologies. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14 and remained in place until 24-hour assessments were completed.

Time frame:
Baseline (day -1) and day 14
Reported as:
Number · Participants
Number of Participants With Arrhythmias as Assessed by Continuous Holter Monitoring.
ParticipantsPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Average Hourly Daytime Heart Rate < 50 bpm (daytime defined as 7 am-10 pm)(Day-1)00100
Frequent Supraventricular Premature Beats (APBs) (>100/24hrs) (Day-1)21300
Frequent Ventricular Ectopic Beats (VEs) (> 200/24hrs) (Day-1)14102
Other arrhythmias (Day-1)1713151512
Second Degree AV Block - Type I (Day-1)10000
Sinus Bradycardia (HR < 40 bpm)(Day-1)00100
SupraVentricular Tachycardia (lasting > 10 beats) (Day-1)45421
At least three monomorphic beats in a row (Day 14)00010
Average Hourly Daytime Heart Rate < 50 bpm (daytime defined as 7 am-10 pm) (Day 14)00001
Frequent Supraventricular Premature Beats (APBs) (>100/24hrs) (Day 14)10000
Frequent Ventricular Ectopic Beats (VEs) (> 200/24hrs) (Day 14)14001
Other arrhythmias (Day 14)1814131513
Presence of NSVT (Non-Sustained Ventricular Tachycardia) episodes (Day 14)00010
Second Degree AV Block - Type I (Day 14)20000
Second Degree AV Block - Type II(Day 14)10010
Sinus Bradycardia (HR < 40 bpm)00010
SupraVentricular Tachycardia (lasting > 10 beats (Day 14)33111
PrimaryChange From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Standing)

Diastolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in standing position.

Time frame:
Baseline and day 14
Reported as:
Mean · mmHg
Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Standing)
mmHgPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline80.11 ± 4.70276.07 ± 5.25777.67 ± 11.46278.93 ± 6.14777.92 ± 9.768
Day 14 Change from Baseline1.11 ± 9.5792.53 ± 5.540-0.07 ± 12.1370.93 ± 7.2161.62 ± 9.097
PrimaryChange From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Sitting)

Diastolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in sitting position.

Time frame:
Baseline and day 14
Reported as:
Mean · mmHg
Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Sitting)
mmHgPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline77.72 ± 6.54274.27 ± 6.23977.20 ± 10.70574.80 ± 6.77474.15 ± 8.245
Day 14 Change from Baseline0.11 ± 9.292-0.53 ± 6.906-0.79 ± 9.7362.73 ± 9.3841.77 ± 6.366
PrimaryChange From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Standing)

Systolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in standing position.

Time frame:
Baseline and day 14
Reported as:
Mean · mmHg
Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Standing)
mmHgPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline117.83 ± 10.733114.60 ± 8.675121.33 ± 17.867118.87 ± 11.513114.77 ± 15.095
Day 14 Change from Baseline5.11 ± 11.4833.80 ± 13.311-4.43 ± 18.7440.33 ± 12.2345.62 ± 16.536
PrimaryChange From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Sitting)

Systolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in sitting position.

Time frame:
Baseline and day 14
Reported as:
Mean · mmHg
Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Sitting)
mmHgPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline116.39 ± 11.304113.80 ± 9.405119.07 ± 15.931117.20 ± 10.638114.15 ± 14.288
Day 14 Change from Baseline4.17 ± 11.8680.20 ± 10.359-2.79 ± 16.4702.47 ± 16.8905.62 ± 12.672
PrimaryChange From Baseline at Day 14 in Vital Signs: Pulse Rate

Pulse rate was measured just prior to dosing (approx. 30 mins).

Time frame:
Baseline and day 14
Reported as:
Mean · beats/min
Change From Baseline at Day 14 in Vital Signs: Pulse Rate
beats/minPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline69.89 ± 8.62966.00 ± 6.35869.20 ± 9.96668.40 ± 4.61172.62 ± 7.136
Day 14 Change from Baseline1.06 ± 8.271-2.00 ± 8.0270.14 ± 7.2630.27 ± 8.388-11.00 ± 9.618
PrimaryChange From Baseline at Day 14 in Vital Signs: Respiratory Rate

Respiratory rate was measured just prior to dosing (approx. 30 mins).

Time frame:
Baseline and day 14
Reported as:
Mean · breaths/min
Change From Baseline at Day 14 in Vital Signs: Respiratory Rate
breaths/minPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline15.39 ± 1.37815.47 ± 1.72715.73 ± 1.62415.60 ± 1.50215.85 ± 1.573
Day 14 Change from Baseline-0.11 ± 2.220-0.40 ± 2.1970.07 ± 1.940-0.43 ± 2.065-1.33 ± 1.923
PrimaryChange From Baseline at Day 14 in Vital Signs: Oxygen Saturation

Oxygen Saturation was measured just prior to dosing (approx. 30 mins).

Time frame:
Baseline and day 14
Reported as:
Mean · Percentage of Oxygen satuartion
Change From Baseline at Day 14 in Vital Signs: Oxygen Saturation
Percentage of Oxygen satuartionPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline98.50 ± 1.09898.40 ± 1.40497.87 ± 1.72797.67 ± 1.49697.31 ± 1.251
Day 14 Change from Baseline-0.61 ± 1.539-0.73 ± 1.4860.29 ± 2.0910.20 ± 1.4240.38 ± 1.193
PrimaryChange From Baseline at Day 14 in Vital Signs: Oral Body Temperature

Temperature was measured just prior to dosing (approx. 30 mins).

Time frame:
Baseline and day 14
Reported as:
Mean · Degree Celius
Change From Baseline at Day 14 in Vital Signs: Oral Body Temperature
Degree CeliusPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline36.77 ± 0.19036.65 ± 0.15536.79 ± 0.16236.71 ± 0.16836.77 ± 0.361
Day 14 Change from Baseline-0.04 ± 0.2430.06 ± 0.172-0.09 ± 0.264-0.01 ± 0.239-0.05 ± 0.458
PrimaryChange From Baseline at Day 14 in Vital Signs: Weight

Weight was measured just prior to dosing (approx. 30 mins).

Time frame:
Baseline and day 14
Reported as:
Mean · Kilograms
Change From Baseline at Day 14 in Vital Signs: Weight
KilogramsPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline73.25 ± 10.11570.85 ± 11.82173.47 ± 14.93472.10 ± 7.10472.73 ± 12.047
Day 14 Change from Baseline0.36 ± 1.0340.51 ± 0.9830.24 ± 0.9160.15 ± 0.9260.01 ± 0.704
PrimaryChange From Baseline at Day 15 for Laboratory Hormones Results : Adrenocorticotropic Hormone (ADTH) and Estradiol.

Blood samples for the assessment of ACTH and Estradiol were collected upon participants admission to the unit.

Time frame:
Baseline and day 15
Reported as:
Mean · pmol/L
Change From Baseline at Day 15 for Laboratory Hormones Results : Adrenocorticotropic Hormone (ADTH) and Estradiol.
pmol/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (ADTH)5.34 ± 3.4024.17 ± 1.9913.87 ± 2.3613.55 ± 2.3603.27 ± 2.011
Day 15 Change from Baseline (ADTH)-0.49 ± 3.333-0.68 ± 2.0350.84 ± 1.9141.04 ± 3.0591.67 ± 3.059
Baseline (Estradiol)57.33 ± 43.23659.49 ± 40.12935.02 ± 25.55643.83 ± 31.27062.42 ± 42.589
Day 15 Change from Baseline (Estradiol)22.43 ± 141.61813.21 ± 80.7040.53 ± 3.1721.96 ± 12.394-9.02 ± 87.480
PrimaryChange From Baseline at Day 15 for Laboratory Hormones Results: Follicle Stimulating Hormone

Blood samples for the assessment of Follicle Stimulating were collected upon participants admission to the unit.

Time frame:
Baseline and day 15
Reported as:
Mean · IU/L
Change From Baseline at Day 15 for Laboratory Hormones Results: Follicle Stimulating Hormone
IU/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline76.01 ± 23.122100.87 ± 36.81377.78 ± 20.13288.77 ± 42.25170.59 ± 17.046
Day 15 Change from Baseline5.98 ± 13.072-2.29 ± 20.9484.09 ± 8.3536.73 ± 6.9048.92 ± 13.409
PrimaryChange From Baseline at Day 15 for Laboratory Hormones Results : Triiodothyronine Uptake

Blood samples for the assessment of Triiodothyronine were collected upon participants admission to the unit.

Time frame:
Baseline and day 15
Reported as:
Mean · Percentage of T Uptake
Change From Baseline at Day 15 for Laboratory Hormones Results : Triiodothyronine Uptake
Percentage of T UptakePlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline32.300 ± 3.562330.800 ± 2.471230.838 ± 1.796830.671 ± 1.3060—
Day 15 Change from Baseline-0.720 ± 0.7662-0.700 ± 0.29440.143 ± 0.71150.443 ± 1.0130—
PrimaryChange From Baseline at Day 15 for Laboratory Hormones Results: Thyrotropin

Blood samples for the assessment of Thyrotropin were collected upon participants admission to the unit.

Time frame:
Baseline and day 15
Reported as:
Mean · mIU/L
Change From Baseline at Day 15 for Laboratory Hormones Results: Thyrotropin
mIU/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline2.658 ± 1.75841.800 ± 0.98302.451 ± 1.48112.785 ± 1.14492.330 ± 1.2658
Day 15 Change from Baseline-0.959 ± 1.3501-0.571 ± 0.8148-0.648 ± 0.5903-0.823 ± 1.0604-0.616 ± 1.1375
PrimaryChange From Baseline at Day 15 for Laboratory Hormones Results : Cortisol, Testosterone, Thyroxine and Triiodothyronine

Blood samples for the assessment of Cortisol, Testosterone, Thyroxine and Triiodothyronine were collected upon participants admission to the unit.

Time frame:
Baseline and day 15
Reported as:
Mean · nmol/L
Change From Baseline at Day 15 for Laboratory Hormones Results : Cortisol, Testosterone, Thyroxine and Triiodothyronine
nmol/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Cortisol)348.60 ± 156.496337.16 ± 177.507345.91 ± 173.302251.66 ± 144.743230.42 ± 74.560
Day 15 Change from Baseline (Cortisol)15.94 ± 193.564-23.32 ± 172.68568.05 ± 170.12192.02 ± 159.464127.20 ± 208.452
Baseline (Testosterone)0.744 ± 0.38500.666 ± 0.62300.517 ± 0.23170.433 ± 0.29610.611 ± 0.4271
Day 15 Change from Baseline (Testosterone)0.057 ± 0.35670.024 ± 0.25780.696 ± 0.33670.480 ± 0.45890.524 ± 0.2905
Baseline(Thyroxine)95.44 ± 14.57695.66 ± 15.20396.11 ± 14.64586.41 ± 16.11694.16 ± 22.180
Day 15 Change from Baseline(Thyroxine)-3.78 ± 14.771-1.28 ± 8.127-10.67 ± 26.3246.53 ± 9.5460.88 ± 13.720
Baseline(Triiodothyronine)1.865 ± 0.141312.060 ± 0.31741.980 ± 0.29161.776 ± 0.45102.163 ± 0.6008
Day 15 Change from Baseline (Triiodothyronine)-0.190 ± 0.3171-0.141 ± 0.2742-0.407 ± 0.2180-0.148 ± 0.1883-0.416 ± 0.5359
PrimaryChange From Baseline at Day 14 for Clinical Laboratory Parameters LIPIDS : Cholesterol, Triglycerides, HDL Cholesterol and LDL Cholesterol.

Blood samples for the assessment of Cholesterol, Triglycerides,high-density lipoprotein (HDL)Cholesterol and low-density lipoprotein (LDL) Cholesterol were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · mmol/L
Change From Baseline at Day 14 for Clinical Laboratory Parameters LIPIDS : Cholesterol, Triglycerides, HDL Cholesterol and LDL Cholesterol.
mmol/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Cholesterol)5.434 ± 1.02235.471 ± 0.65925.391 ± 0.73465.804 ± 0.64625.393 ± 0.9008
Day 14 Change from Baseline (Cholesterol)0.088 ± 0.8629-0.061 ± 0.4761-0.205 ± 0.8981-0.185 ± 0.6386-0.321 ± 0.6790
Baseline (Triglycerides)1.163 ± 0.57961.185 ± 0.50361.131 ± 0.58891.329 ± 0.62451.353 ± 0.5540
Day 14 Change from Baseline (Triglycerides)0.048 ± 0.4936-0.071 ± 0.4725-0.116 ± 0.5247-0.029 ± 0.4178-0.172 ± 0.5633
Baseline(HDL Cholesterol)1.717 ± 0.45251.879 ± 0.40521.7444 ± 0.65631.768 ± 0.47161.449 ± 0.2752
Day 14 Change from Baseline( HDL Cholesterol)-0.167 ± 0.2824-0.219 ± 0.2015-0.056 ± 0.2559-0.147 ± 0.1546-0.158 ± 0.3132
Baseline( LDL Cholesterol)3.226 ± 1.04853.125 ± 0.84363.172 ± 0.76543.625 ± 0.71883.552 ± 1.1088
Day 14 Change from Baseline ( LDL Cholesterol)-0.013 ± 0.39260.184 ± 0.2958-0.119 ± 0.6747-0.038 ± 0.6490-0.053 ± 0.5944
PrimaryChange From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils and Immature Granulocytes.

Blood samples for the assessment of Neutrophils/Leukocytes, Lymphocytes /Leukocytes, Monocytes/Leukocytes, Eosinophils/Leukocytes, Basophils/Leukocytes and Immature Granulocytes/ Leukocytes were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · Percentage of total white blood cells
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils and Immature Granulocytes.
Percentage of total white blood cellsPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Neutrophils/ Leukocytes)56.53 ± 7.70053.31 ± 4.99455.65 ± 8.31854.78 ± 8.61050.92 ± 10.316
Day 14 Change from Baseline (Neutrophils/ Leukocytes)-0.29 ± 7.7882.41 ± 6.119-0.50 ± 5.047-0.98 ± 7.116-2.69 ± 10.614
Baseline (Lymphocytes/ Leukocytes)32.40 ± 7.09835.57 ± 5.43933.33 ± 8.02434.33 ± 7.44436.78 ± 10.446
Day 14 Change from Baseline(Lymphocytes / Leukocytes)0.18 ± 5.791-2.46 ± 5.667-0.11 ± 4.7630.59 ± 5.8352.75 ± 10.926
Baseline ( Monocytes / Leukocytes )7.58 ± 1.5927.47 ± 1.3797.62 ± 1.5917.71 ± 1.7628.62 ± 3.276
Day 14 Change from Baseline( Monocytes/ Leukocytes)0.22 ± 1.947-0.15 ± 1.7510.65 ± 1.2910.05 ± 2.7580.22 ± 3.850
Baseline ( Eosinophils/ Leukocytes)2.83 ± 2.4333.04 ± 3.3522.64 ± 1.4222.61 ± 1.1703.05 ± 1.979
Day 14 Change from Baseline(Eosinophils/ Leukocytes)0.02 ± 1.3160.29 ± 0.9610.06 ± 0.7940.33 ± 0.538-0.24 ± 1.189
Baseline(Basophils/ Leukocytes)0.61 ± 0.2630.55 ± 0.1770.66 ± 0.2950.51 ± 0.2230.56 ± 0.373
Day 14 Change from Baseline (Basophils/ Leukocytes)-0.13 ± 0.181-0.07 ± 0.111-0.14 ± 0.1220.01 ± 0.209-0.05 ± 0.307
Baseline( Immature Granulocytes/ Leukocytes)0.15 ± 0.0840.25 ± 0.1000.20 ± 0.1510.13 ± 0.1110.15 ± 0.084
Day 14 Change from Baseline( Immature Granulocytes/ Leukocytes)0.03 ± 0.082-0.05 ± 0.1000.09 ± 0.1570.00 ± 0.1830.03 ± 0.137
PrimaryChange From Baseline at Day 14 for Clinical Laboratory Parameters HEMATOLOGY: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets.

Blood samples for the assessment of Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets were collected upon participant's admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · 10^9*cells/L
Change From Baseline at Day 14 for Clinical Laboratory Parameters HEMATOLOGY: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets.
10^9*cells/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline( Leukocytes)6.73 ± 1.3726.54 ± 1.6136.75 ± 1.2456.78 ± 1.3076.60 ± 1.896
Day 14 Change from Baseline( Leukocytes)-0.60 ± 1.299-0.27 ± 1.134-0.34 ± 0.686-0.80 ± 1.011-0.06 ± 1.650
Baseline (Neutrophils)3.847 ± 1.08993.493 ± 0.97373.779 ± 0.93323.745 ± 0.96863.394 ± 1.3264
Day 14 Change from Baseline (Neutrophils )-0.374 ± 1.17940.072 ± 0.7422-0.246 ± 0.5487-0.539 ± 0.9017-0.186 ± 1.4444
Baseline (Lymphocytes)2.148 ± 0.49052.341 ± 0.70092.242 ± 0.61992.320 ± 0.64672.429 ± 0.9032
Day 14 Change from Baseline (Lymphocytes)-0.172 ± 0.2900-0.301 ± 0.5336-0.107 ± 0.3652-0.237 ± 0.39010.142 ± 0.6749
Baseline ( Monocytes)0.499 ± 0.09840.479 ± 0.10510.505 ± 0.09900.524 ± 0.14100.534 ± 0.1552
Day 14 Change from Baseline( Monocytes)-0.033 ± 0.1117-0.030 ± 0.13240.019 ± 0.0895-0.057 ± 0.19410.002 ± 0.1643
Baseline ( Eosinophils)0.202 ± 0.23250.185 ± 0.18140.177 ± 0.10900.177 ± 0.09540.208 ± 0.1592
Day 14 Change from Baseline(Eosinophils)-0.017 ± 0.09950.021 ± 0.0719-0.006 ± 0.05490.005 ± 0.0436-0.028 ± 0.1155
Baseline(Basophils)0.041 ± 0.03050.031 ± 0.02640.028 ± 0.03210.027 ± 0.03010.030 ± 0.327
Day 14 Change from Baseline(Basophils)-0.008 ± 0.0148-0.007 ± 0.0090-0.001 ± 0.0305-0.010 ± 0.0259-0.002 ± 0.0060
Baseline( Immature Granulocytes)0.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.00
Day 14 Change from Baseline( Immature Granulocytes)0.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.00
Baseline (Platelets )263.4 ± 59.66249.1 ± 61.67269.8 ± 61.40261.9 ± 46.91258.2 ± 52.57
Day 14 Change from Baseline(Platelets )8.1 ± 17.774.5 ± 33.8313.5 ± 29.6721.6 ± 24.5820.8 ± 74.35
PrimaryChange From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin Concentration

Blood samples for the assessment of Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HB)concentration were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · g/L
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin Concentration
g/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Hemoglobin)128.9 ± 8.53132.4 ± 10.64128.7 ± 7.82127.7 ± 8.60132.2 ± 12.60
Day 14 Change from Baseline (Hemoglobin)-11.8 ± 4.99-9.0 ± 7.14-14.6 ± 5.98-13.9 ± 4.66-12.1 ± 6.58
Baseline (Erythrocytes Mean Corpuscular HB concentration )328.5 ± 10.30335.2 ± 9.42329.0 ± 10.22328.2 ± 7.51326.8 ± 10.27
Day 14 Change from Baseline (Erythrocytes Mean Corpuscular HB concentration)-0.4 ± 5.21-2.5 ± 2.34-2.3 ± 6.94-0.8 ± 3.413.2 ± 4.62
PrimaryChange From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes

Blood samples for the assessment of Erythrocytes were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · 10^12*cells/L
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes
10^12*cells/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline4.467 ± 0.25034.525 ± 0.22124.459 ± 0.29624.365 ± 0.36784.518 ± 0.2368
Day 14 Change from Baseline-0.421 ± 0.1750-0.301 ± 0.2694-0.511 ± 0.2111-0.485 ± 0.1903-0.425 ± 0.2297
PrimaryChange From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume.

Blood samples for the assessment of Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · fL
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume.
fLPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Erythrocytes Mean Corpuscular Volume )87.87 ± 5.70787.69 ± 3.89087.71 ± 4.71789.42 ± 6.74488.63 ± 3.150
Day 14 Change from Baseline (Erythrocytes Mean Corpuscular Volume )0.44 ± 1.1550.11 ± 0.7990.47 ± 0.9670.49 ± 1,691-0.27 ± 0.659
Baseline (Mean Platelet Volume)9.79 ± 0.8099.91 ± 1.60810.22 ± 1.56510.19 ± 1.00510.05 ± 1.179
Day 14 Change from Baseline (Mean Platelet Volume)-0.14 ± 0.4480.08 ± 0.412-0.24 ± 0.220-0.37 ± 0.403-0.06 ± 0.216
PrimaryChange From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples for the assessment of Erythrocytes Mean Corpuscular Hemoglobin were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · pg
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Hemoglobin
pgPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline28.89 ± 2.51729.50 ± 1.80328.79 ± 2.21729.39 ± 2.51128.89 ± 1.759
Day 14 Change from Baseline0.09 ± 0.494-0.19 ± 0.2630.03 ± 0.4860.15 ± 0.5320.17 ± 0.317
PrimaryChange From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Distribution Width.

Blood samples for the assessment of Erythrocytes Distribution Width were collected upon participants admission to the unit. Erythrocytes distribution width (in percentage) = 1 SD of Erythrocyte volume/MCV x 100%

Time frame:
Baseline and day 14
Reported as:
Mean · Percentage of Erythrocyte volume
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Distribution Width.
Percentage of Erythrocyte volumePlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline27.81 ± 15.47825.52 ± 15.41335.82 ± 16.47630.59 ± 16.08931.48 ± 17.013
Day 14 Change from Baseline-0.15 ± 0.9160.49 ± 0.863-0.05 ± 1.878-0.61 ± 0.696-0.68 ± 0.778
PrimaryChange From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hematocrit.

Blood samples for the assessment of Hematocrit were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · Volume percentage
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hematocrit.
Volume percentagePlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline39.18 ± 1.97639.63 ± 2.46138.99 ± 1.78838.85 ± 1.99040.02 ± 2.646
Day 14 Change from Baseline-3.51 ± 1.307-2.45 ± 2.106-4.20 ± 1.877-4.13 ± 1.431-3.86 ± 2.163
PrimaryChange From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Protein and Albumin.

Blood samples for the assessment of Protein and Albumin were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · g/L
Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Protein and Albumin.
g/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Protein)71.8 ± 4.5472.2 ± 4.1374.3 ± 4.2570.5 ± 4.8469.2 ± 4.22
Day 14 Change from Baseline(Protein)-4.0 ± 3.11-2.5 ± 4.39-6.9 ± 4.89-4.1 ± 2.64-2.5 ± 3.10
Baseline(Albumin)42.9 ± 6.7544.3 ± 1.8444.4 ± 2.5344.7 ± 2.5343.2 ± 2.67
Day 14 Change from Baseline (Albumin)-0.6 ± 6.42-2.5 ± 2.42-3.2 ± 2.080.3 ± 2.05-1.8 ± 2.44
PrimaryChange From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase

Blood samples for the assessment of Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · ukat/L
Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase
ukat/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Alkaline Phosphatase)1.587 ± 0.48291.397 ± 0.32331.364 ± 0.32191.397 ± 0.32711.407 ± 0.4417
Day 14 Change from Baseline (Alkaline Phosphatase)-0.129 ± 0.3411-0.130 ± 0.2054-0.172 ± 0.1533-0.203 ± 0.2576-0.131 ± 0.2958
Baseline(Alanine Aminotransferase)0.295 ± 0.13020.331 ± 0.14940.279 ± 0.11510.313 ± 0.12810.413 ± 0.1755
Day 14 Change from Baseline (Alanine Aminotransferase)0.108 ± 0.4103-0.049 ± 0.10530.049 ± 0,2099-0.016 ± 0.13910.052 ± 0.3923
Baseline (Aspartate Aminotransferase)0.344 ± 0.07600.355 ± 0.06320.343 ± 0.09500.352 ± 0.07370.401 ± 0.1976
Day 14 Change from Baseline (Aspartate Aminotransferase)0.041 ± 0.2197-0.035 ± 0.0542-0.032 ± 0.1030-0.009 ± 0.0743-0.032 ± 0.2851
Baseline (Gamma Glutamyl Transferase)0.309 ± 0.17400.324 ± 0.20850.397 ± 0.21110.561 ± 0.79980.372 ± 0.2272
Day 14 Change from Baseline (Gamma Glutamyl Transferase)0.101 ± 0.3890-0.035 ± 0.09800.001 ± 0.1606-0.190 ± 0.46200.015 ± 0.1959
Baseline (Creatine Kinase)1.957 ± 0.88722.047 ± 1.01461.907 ± 1.19331.895 ± 1.26381.886 ± 1.1854
Day 14 Change from Baseline (Creatine Kinase)0.021 ± 0.9758-0.260 ± 0.4338-0.252 ± 0.5078-0.038 ± 0.5689-0.269 ± 0.5032
PrimaryChange From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Urate, Bilirubin and Creatinine.

Blood samples for the assessment of Urate, Bilirubin and Creatinine were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · umol/L
Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Urate, Bilirubin and Creatinine.
umol/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Urate)297.43 ± 41.896318.23 ± 20.323261.74 ± 57.222275.34 ± 75.528212.17 ± 52.885
Day 14 Change from Baseline (Urate)-11.90 ± 41.380-2.95 ± 28.5112.57 ± 19.706-12.76 ± 28.636-7.93 ± 44.269
Baseline (Bilirubin)7.61 ± 3.5008.44 ± 3.6407.19 ± 2.9326.96 ± 2.6527.23 ± 3.305
Day 14 Change from Baseline(Bilirubin)-1.25 ± 3.225-1.15 ± 2.654-1.00 ± 1.886-0.01 ± 2.5990.40 ± 3.069
Baseline(Creatinine)71.162 ± 11.321567.125 ± 8.071165.121 ± 9.886767.891 ± 9.163611.844 ± 8.9096
Day 14 Change from Baseline(Creatinine)2.652 ± 6.4810-1.885 ± 7.8090-4.168 ± 7.6761-1.297 ± 6.6136-3.605 ± 5.6665
PrimaryChange From Baseline at Day 14 for Clinical Laboratory Parameters CHEMISTRY: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen.

Blood samples for the assessment of Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen were collected upon participant's admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · mmol/L
Change From Baseline at Day 14 for Clinical Laboratory Parameters CHEMISTRY: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen.
mmol/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Sodium)140.7 ± 2.93140.3 ± 2.05140.0 ± 1.65142.3 ± 3.01140.0 ± 2.83
Day 14 Change from Baseline (Sodium)-0.9 ± 2.91-0.7 ± 2.97-0.5 ± 2.28-2.5 ± 3.230.7 ± 3.47
Baseline (Potassium)4.41 ± 0.3754.22 ± 0.2464.29 ± 0.3744.49 ± 0.3804.14 ± 0.421
Day 14 Change from Baseline (Potassium)0.06 ± 0.4780.22 ± 0.3230.15 ± 0.427-0.06 ± 0.4080.31 ± 0.614
Baseline (Chloride)102.8 ± 2.94102.4 ± 3.79100.7 ± 2.32102.7 ± 2.84101.4 ± 1.56
Day 14 Change from Baseline ( Chloride)-1.2 ± 3.200.4 ± 3.161.1 ± 1.69-1.1 ± 3.020.8 ± 2.88
Baseline (Bicarbonate)26.39 ± 2.61526.60 ± 2.13127.47 ± 1.64226.20 ± 1.69927.62 ± 3.641
Day 14 Change from Baseline (Bicarbonate)1.11 ± 3.660-0.93 ± 3.5751.00 ± 3.0882.00 ± 2.2040.31 ± 2.626
Baseline (Calcium)2.421 ± 0.08032.401 ± 0.07302.515 ± 0.09982.411 ± 0.06222.382 ± 0.0928
Day 14 Change from Baseline (Calcium)-0.032 ± 0.1198-0.044 ± 0.1355-0.144 ± 0.1147-0.049 ± 0.0630-0.052 ± 0.1103
Baseline (Phosphate)1.240 ± 0.15101.249 ± 0.12771.268 ± 0.12691.280 ± 0.11151.272 ± 0.1544
Day 14 Change from Baseline (Phosphate)0.026 ± 0.1602-0.045 ± 0.1457-0.052 ± 0.10960.027 ± 0.1389-0.038 ± 0.2171
Baseline (Glucose)5.457 ± 0.64175.521 ± 0.41575.349 ± 0.49575.483 ± 0.39435.456 ± 0.4401
Day 14 Change from Baseline (Glucose)-0.113 ± 0.9083-0.278 ± 0.4006-0.173 ± 0.3412-0.098 ± 0.42450.025 ± 0.3063
Baseline (Magnesium)0.893 ± 0.07320.885 ± 0.05880.881 ± 0.06750.905 ± 0.07030.896 ± 0.0836
Day 14 Change from Baseline (Magnesium)-0.009 ± 0.04600.001 ± 0.03870.001 ± 0.05290.006 ± 0.0484-0.027 ± 0.0696
Baseline (Urea Nitrogen)5.59 ± 1.2305.47 ± 1.3374.67 ± 1.2745.30 ± 1.1985.21 ± 1.393
Day 14 Change from Baseline (Urea Nitrogen)0.14 ± 2.359-0.14 ± 1.0700.20 ± 0.8260.00 ± 1.442-0.38 ± 1.488
PrimaryLaboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at Baseline

Blood samples for the assessment of Glomerular Filtration Rate African were collected upon participants admission to the unit.

Time frame:
At Baseline
Reported as:
Mean · mL/sec/1.73m^2
Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at Baseline
mL/sec/1.73m^2Placebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at Baseline1.628 ± 0.23471.759 ± 0.15921.580 ± 0.18461.557 ± 0.15531.666 ± 0.1885
PrimaryLaboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at Baseline

Blood samples for the assessment of Glomerular Filtration Rate Caucasian were collected upon participants admission to the unit.

Time frame:
At Baseline
Reported as:
Mean · mL/sec/1.73m^2
Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at Baseline
mL/sec/1.73m^2Placebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at Baseline1.343 ± 0.19551.450 ± 0.12651.300 ± 0.15031.290 ± 0.12731.378 ± 0.1482
PrimaryChange From Baseline at Day 14 for COAGULATION: Prothrombin International Normalized Ratio (INR)

Blood samples for the assessment of Prothrombin International Normalized Ratio were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · INR
Change From Baseline at Day 14 for COAGULATION: Prothrombin International Normalized Ratio (INR)
INRPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline0.993 ± 0.04281.013 ± 0.05521.007 ± 0.04820.991 ± 0.04650.993 ± 0.0645
Day 14 Change from Baseline-0.007 ± 0.0546-0.038 ± 0.04710.016 ± 0.06650.013 ± 0.03590.057 ± 0.2311
PrimaryChange From Baseline at Day 14 for COAGULATION: Prothrombin Time and Activated Partial Thromboplastin Time

Blood samples for the assessment of Prothrombin Time and Activated Partial Thromboplastin Time were collected upon participants admission to the unit.

Time frame:
Baseline and day 14
Reported as:
Mean · sec
Change From Baseline at Day 14 for COAGULATION: Prothrombin Time and Activated Partial Thromboplastin Time
secPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Prothrombin Time )11.17 ± 1.87111.05 ± 1.67911.91 ± 1.87111.51 ± 1.75711.47 ± 1.589
Day 14 Change from Baseline (Prothrombin Time)-0.15 ± 0.507-0.32 ± 0.3510.12 ± 0.5030.11 ± 0.2910.55 ± 2.363
Baseline(Activated Partial Thromboplastin Time)26.91 ± 2.43527.09 ± 2.49528.14 ± 2.48327.50 ± 2.87227.55 ± 3.009
Day 14 Change from Baseline (Activated Partial Thromboplastin Time)-0.82 ± 1.350-1.80 ± 1.489-0.81 ± 1.478-0.87 ± 1.3960.58 ± 3.196
PrimaryHeart Rate (HR) - Change From Baseline (Day -1) at Day 14

Heart rate was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made.Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

Time frame:
Baseline (day -1) and day 14
Reported as:
Mean · beats/min
Heart Rate (HR) - Change From Baseline (Day -1) at Day 14
beats/minPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day -1(Predose)65.7 ± 9.5061.6 ± 6.4365.3 ± 8.4364.5 ± 5.8565.0 ± 7.16
Day -1 (0.5 hour)68.5 ± 9.5464.5 ± 8.7666.7 ± 10.5666.1 ± 9.1368.7 ± 9.94
Day -1 (1 hour)69.8 ± 9.2766.8 ± 9.5866.2 ± 9.3167.6 ± 5.6967.2 ± 7.77
Day -1 (1.5 hour)68.9 ± 9.2667.3 ± 7.2466.5 ± 9.0967.3 ± 5.3867.5 ± 7.37
Day -1 (2 hour)70.2 ± 10.9567.3 ± 7.8165.9 ± 9.9665.2 ± 4.3866.3 ± 8.36
Day -1 (2.5 hour)68.7 ± 9.0269.4 ± 8.8664.6 ± 10.1165.1 ± 4.1968.2 ± 10.32
Day -1 (3 hour)69.4 ± 9.0664.3 ± 4.9165.6 ± 7.8967.9 ± 5.7968.8 ± 7.51
Day -1 (4 hour)68.0 ± 10.5062.8 ± 6.7064.3 ± 6.2063.9 ± 5.5467.5 ± 8.40
Day -1 (8 hour)72.9 ± 10.3864.4 ± 5.9570.2 ± 10.6866.9 ± 7.1770.2 ± 8.14
Day -1 (12 hour)77.0 ± 9.6368.7 ± 8.9673.6 ± 7.4370.7 ± 7.8171.6 ± 8.69
Day 14 (Pre dose) Change from Baseline-0.4 ± 6.87-0.3 ± 4.080.8 ± 6.14-2.1 ± 6.96-3.8 ± 8.85
Day 14 (0.5 hour) Change from Baseline-2.6 ± 7.58-5.1 ± 8.48-0.9 ± 10.10-4.3 ± 10.24-9.6 ± 10.13
Day 14 (1 hour) Change from Baseline-5.0 ± 8.66-6.7 ± 9.65-0.6 ± 9.18-7.9 ± 8.35-7.7 ± 6.92
Day 14 (1.5 hour) Change from Baseline-5.5 ± 8.13-7.4 ± 7.24-1.5 ± 7.10-7.9 ± 8.07-7.6 ± 8.08
Day 14 (2 hour) Change from Baseline-6.5 ± 10.98-7.9 ± 7.98-2.4 ± 8.54-4.2 ± 7.90-7.0 ± 6.94
Day 14 (2.5 hour) Change from Baseline-4.2 ± 7.16-10.5 ± 8.60-0.3 ± 7.05-4.2 ± 4.95-7.8 ± 10.48
Day 14 (3 hour) Change from Baseline-4.9 ± 9.94-4.6 ± 5.05-0.4 ± 8.45-7.5 ± 7.74-5.7 ± 9.94
Day 14 (4 hour) Change from Baseline-4.3 ± 8.57-2.9 ± 4.830.2 ± 8.86-2.0 ± 7.36-5.8 ± 7.62
Day 14 (8 hour) Change from Baseline-2.2 ± 6.220.5 ± 5.156.8 ± 8.991.0 ± 6.47-2.3 ± 9.40
Day 14 (12 hour) Change from Baseline-0.9 ± 5.700.7 ± 5.742.3 ± 8.260.0 ± 5.49-3.2 ± 9.57
PrimaryMean PR Interval - Change From Baseline (Day -1) at Day 14

PR Interval was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

Time frame:
Baseline (day -1) and day 14
Reported as:
Mean · msec
Mean PR Interval - Change From Baseline (Day -1) at Day 14
msecPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day -1 (Predose)165.3 ± 22.20152.6 ± 14.30165.3 ± 26.10166.6 ± 26.74162.6 ± 20.52
Day -1 (0.5 hour)163.3 ± 24.69155.3 ± 20.19167.1 ± 26.74162.1 ± 22.13162.4 ± 20.59
Day -1 (1 hour)166.3 ± 23.76155.7 ± 20.43166.6 ± 25.79166.5 ± 24.32162.1 ± 19.82
Day -1 (1.5 hour)167.6 ± 22.91158.9 ± 17.73165.9 ± 21.47164.9 ± 26.07162.4 ± 17.60
Day -1 (2 hour)166.9 ± 25.01156.0 ± 18.95167.1 ± 22.27164.9 ± 25.23162.9 ± 21.16
Day -1 (2.5 hour)168.7 ± 26.32155.3 ± 18.32165.8 ± 26.24165.2 ± 26.51160.4 ± 21.99
Day -1 (3 hour)168.0 ± 25.66153.7 ± 17.61170.1 ± 31.39161.8 ± 23.66160.1 ± 20.10
Day -1 (4 hour)165.6 ± 24.06155.4 ± 17.27165.1 ± 20.73163.6 ± 26.48161.6 ± 16.78
Day -1 (8 hour)162.1 ± 23.67152.5 ± 17.45161.7 ± 22.93163.5 ± 25.00156.4 ± 16.60
Day -1 (12 hour)165.7 ± 26.90157.7 ± 17.41158.5 ± 19.56159.0 ± 21.78156.5 ± 17.71
Day 14 (Pre dose) Change from Baseline5.6 ± 12.321.7 ± 6.41-1.8 ± 10.85-0.3 ± 9.420.9 ± 12.78
Day 14 (0.5 hour) Change from Baseline8.5 ± 20.000.4 ± 6.900.9 ± 14.644.6 ± 12.49-0.8 ± 13.90
Day 14 (1 hour) Change from Baseline5.6 ± 15.882.8 ± 9.03-1.0 ± 14.152.7 ± 19.241.7 ± 13.74
Day 14 (1.5 hour) Change from Baseline-1.0 ± 12.86-2.8 ± 9.593.9 ± 17.63-0.5 ± 11.471.8 ± 17.08
Day 14 (2 hour) Change from Baseline4.1 ± 12.560.6 ± 8.85-0.9 ± 17.720.9 ± 11.824.2 ± 14.32
Day 14 (2.5 hour) Change from Baseline2.2 ± 9.342.6 ± 13.330.0 ± 11.961.8 ± 12.118.3 ± 15.96
Day 14 (3 hour) Change from Baseline3.8 ± 11.095.3 ± 11.40-3.1 ± 10.834.5 ± 15.014.9 ± 14.78
Day 14 (4 hour) Change from Baseline5.7 ± 15.131.4 ± 6.485.2 ± 20.771.8 ± 14.492.2 ± 9.05
Day 14 (8 hour) Change from Baseline1.4 ± 8.662.9 ± 5.950.1 ± 15.03-3.9 ± 12.215.2 ± 6.54
Day 14 (12 hour) Change from Baseline-0.4 ± 8.83-3.6 ± 9.17-0.1 ± 11.072.0 ± 9.330.9 ± 10.80
PrimaryMean QRS Duration - Change From Baseline (Day -1) at Day 14

QRS Duration was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

Time frame:
Baseline (day -1) and day 14
Reported as:
Mean · msec
Mean QRS Duration - Change From Baseline (Day -1) at Day 14
msecPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day -1(Predose)88.8 ± 10.8293.6 ± 8.1184.7 ± 6.3989.2 ± 10.9989.5 ± 11.76
Day -1 (0.5 hour88.7 ± 10.4494.5 ± 7.9487.4 ± 8.4488.5 ± 10.8688.9 ± 10.73
Day -1 (1 hour)88.7 ± 10.2293.3 ± 7.1785.2 ± 7.9490.3 ± 9.9191.2 ± 13.04
Day -1 (1.5 hour)89.4 ± 11.7791.7 ± 8.5285.0 ± 7.9889.5 ± 10.2092.2 ± 11.59
Day -1 (2 hour)86.4 ± 11.0890.5 ± 7.9884.0 ± 5.8389.5 ± 11.1589.0 ± 10.04
Day -1 (2.5 hour)87.6 ± 12.2791.5 ± 8.9484.4 ± 8.2289.0 ± 10.2787.8 ± 10.80
Day -1 (3 hour)86.4 ± 10.1092.7 ± 6.9485.7 ± 9.3288.6 ± 10.1087.9 ± 11.06
Day -1 (4 hour)86.2 ± 11.6892.3 ± 8.2685.1 ± 9.6887.7 ± 11.0488.7 ± 11.53
Day -1 (8 hour)85.4 ± 11.2690.9 ± 9.1681.1 ± 4.4185.4 ± 11.7985.3 ± 11.46
Day -1 (12 hour)86.6 ± 10.5392.0 ± 7.9385.5 ± 9.1386.3 ± 10.5588.1 ± 13.08
Day 14 (Pre dose) Change from Baseline-0.7 ± 3.630.3 ± 3.89-0.8 ± 4.56-0.1 ± 6.713.1 ± 7.80
Day 14 (0.5 hour) Change from Baseline1.0 ± 7.64-1.2 ± 5.87-3.1 ± 5.370.4 ± 6.532.8 ± 5.06
Day 14 (1 hour) Change from Baseline0.7 ± 6.660.0 ± 3.57-1.6 ± 7.46-0.1 ± 8.88-2.5 ± 10.73
Day 14 (1.5 hour) Change from Baseline-0.8 ± 6.001.5 ± 6.83-2.0 ± 6.263.4 ± 6.74-1.8 ± 8.62
Day 14 (2 hour) Change from Baseline1.7 ± 8.083.2 ± 5.87-0.8 ± 5.251.9 ± 8.341.0 ± 8.08
Day 14 (2.5 hour) Change from Baseline1.7 ± 7.130.9 ± 4.960.4 ± 7.021.2 ± 5.613.4 ± 7.39
Day 14 (3 hour) Change from Baseline2.2 ± 5.410.5 ± 4.87-1.5 ± 6.56-1.5 ± 7.062.6 ± 8.90
Day 14 (4 hour) Change from Baseline1.9 ± 6.270.5 ± 4.61-2.5 ± 6.4414.8 ± 49.011.7 ± 7.80
Day 14 (8 hour) Change from Baseline-0.3 ± 3.821.5 ± 4.630.4 ± 3.410.9 ± 6.262.5 ± 6.05
Day 14 (12 hour) Change from Baseline-1.7 ± 6.910.3 ± 2.85-3.3 ± 9.28-0.5 ± 5.49-0.8 ± 7.69
PrimaryMean QT Interval - Change From Baseline (Day -1) at Day 14

QT Interval was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

Time frame:
Baseline (day -1) and day 14
Reported as:
Mean · msec
Mean QT Interval - Change From Baseline (Day -1) at Day 14
msecPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day -1 (Predose)421.8 ± 31.07426.4 ± 23.73412.6 ± 29.12421.8 ± 22.12411.3 ± 16.01
Day -1 (0.5 hour412.4 ± 27.58422.0 ± 24.00410.1 ± 29.29417.7 ± 22.13405.6 ± 22.19
Day -1 (1 hour)412.6 ± 22.81414.6 ± 21.41415.6 ± 29.17414.8 ± 21.32406.5 ± 21.20
Day -1 (1.5 hour)413.7 ± 23.60408.4 ± 19.91408.0 ± 23.71414.9 ± 21.19412.3 ± 22.31
Day -1 (2 hour)407.4 ± 25.64405.8 ± 19.18410.7 ± 33.40413.4 ± 20.20412.7 ± 22.32
Day -1 (2.5 hour)411.3 ± 27.10403.4 ± 27.70410.9 ± 32.10418.9 ± 32.10412.4 ± 26.30
Day -1 (3 hour)407.8 ± 25.47411.9 ± 22.80409.9 ± 24.92410.7 ± 23.04401.2 ± 23.18
Day -1 (4 hour)408.3 ± 32.47414.9 ± 20.19411.2 ± 21.83418.1 ± 19.01407.8 ± 16.98
Day -1 (8 hour)398.9 ± 29.10410.3 ± 19.54396.3 ± 26.84405.7 ± 22.57398.5 ± 27.65
Day -1 (12 hour)389.2 ± 28.40407.1 ± 22.55395.5 ± 22.33402.2 ± 26.39394.4 ± 28.85
Day 14 (Pre dose) Change from Baseline-6.8 ± 17.030.2 ± 15.11-9.6 ± 20.16-2.1 ± 24.545.5 ± 21.03
Day 14 (0.5 hour) Change from Baseline2.3 ± 17.738.7 ± 13.13-2.4 ± 23.9010.2 ± 25.3220.8 ± 24.94
Day 14 (1 hour) Change from Baseline6.9 ± 18.7317.8 ± 15.93-7.9 ± 28.7116.3 ± 20.4317.8 ± 22.08
Day 14 (1.5 hour) Change from Baseline11.7 ± 22.9524.5 ± 14.95-0.5 ± 19.0915.7 ± 21.8217.5 ± 21.80
Day 14 (2 hour) Change from Baseline14.2 ± 25.1925.5 ± 18.133.6 ± 25.0416.3 ± 20.7616.2 ± 16.67
Day 14 (2.5 hour) Change from Baseline9.5 ± 25.1828.3 ± 22.661.4 ± 24.5112.9 ± 21.1114.0 ± 23.04
Day 14 (3 hour) Change from Baseline14.2 ± 28.9017.4 ± 15.421.9 ± 18.6618.3 ± 23.6517.8 ± 28.64
Day 14 (4 hour) Change from Baseline12.6 ± 22.9013.5 ± 15.04-2.8 ± 23.915.5 ± 23.9718.3 ± 22.05
Day 14 (8 hour) Change from Baseline2.4 ± 14.71-1.9 ± 12.65-14.2 ± 18.23-3.7 ± 20.766.6 ± 27.45
Day 14 (12 hour) Change from Baseline3.0 ± 17.62-0.8 ± 13.58-12.9 ± 18.71-1.8 ± 16.377.8 ± 24.27
PrimaryMean QTcF Interval (Fridericia's Correction Formula, QTcF) - Change From Baseline (Day -1) at Day 14

Fridericia-corrected QTcF interval was evaluated as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

Time frame:
Baseline (day -1) and day 14
Reported as:
Mean · msec
Mean QTcF Interval (Fridericia's Correction Formula, QTcF) - Change From Baseline (Day -1) at Day 14
msecPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day -1(Predose)432.7 ± 18.75429.0 ± 16.87422.3 ± 14.41431.1 ± 17.28421.8 ± 20.02
Day -1 (0.5 hour)429.2 ± 16.14430.9 ± 18.81422.3 ± 14.40430.1 ± 16.21422.6 ± 15.35
Day -1 (1 hour)432.2 ± 14.68428.3 ± 14.85427.3 ± 16.15430.9 ± 16.46420.8 ± 13.55
Day -1 (1.5 hour)431.7 ± 18.47423.4 ± 17.60420.6 ± 14.81430.5 ± 15.73427.6 ± 15.24
Day -1 (2 hour)427.2 ± 17.33420.5 ± 13.47420.9 ± 15.57424.5 ± 16.55425.2 ± 15.08
Day -1 (2.5 hour)428.7 ± 19.29422.1 ± 21.46418.3 ± 17.41429.9 ± 18.39428.3 ± 17.29
Day -1 (3 hour)426.7 ± 16.64420.3 ± 18.14419.9 ± 15.56427.0 ± 15.46419.0 ± 17.83
Day -1 (4 hour)423.4 ± 19.52420.3 ± 18.14419.9 ± 14.74426.2 ± 13.33423.2 ± 19.46
Day -1 (8 hour)423.8 ± 16.12419.3 ± 15.99415.5 ± 17.53419.7 ± 16.65418.8 ± 25.31
Day -1 (12 hour)421.2 ± 16.25424.2 ± 13.91422.1 ± 11.25423.7 ± 20.16416.8 ± 20.10
Day 14 (Pre dose) Change from Baseline-6.6 ± 11.740.3 ± 12.75-7.9 ± 13.31-6.6 ± 22.83-3.8 ± 13.46
Day 14 (0.5 hour) Change from Baseline-3.0 ± 14.97-2.9 ± 9.31-4.4 ± 10.521.1 ± 14.510.4 ± 12.92
Day 14 (1 hour) Change from Baseline-2.6 ± 11.942.7 ± 11.08-8.4 ± 12.88-1.2 ± 18.181.6 ± 15.34
Day 14 (1.5 hour) Change from Baseline0.1 ± 13.978.3 ± 15.45-3.8 ± 9.02-2.1 ± 15.160.6 ± 15.77
Day 14 (2 hour) Change from Baseline1.3 ± 17.408.7 ± 11.48-0.4 ± 15.256.7 ± 10.090.8 ± 12.58
Day 14 (2.5 hour) Change from Baseline1.1 ± 20.945.9 ± 18.242.3 ± 13.843.8 ± 16.62-2.3 ± 12.11
Day 14 (3 hour) Change from Baseline3.6 ± 13.917.0 ± 17.290.3 ± 7.712.2 ± 12.145.5 ± 15.08
Day 14 (4 hour) Change from Baseline4.6 ± 11.777.1 ± 14.96-3.8 ± 11.340.1 ± 15.556.2 ± 22.76
Day 14 (8 hour) Change from Baseline-2.0 ± 9.55-1.1 ± 10.67-1.3 ± 13.74-1.8 ± 14.032.0 ± 22.20
Day 14 (12 hour) Change from Baseline1.2 ± 14.431.3 ± 10.33-9.4 ± 13.78-1.3 ± 17.432.8 ± 17.21
PrimaryMean QTcB Interval (Bazett's Correction Formula, QTcB) - Change From Baseline (Day -1) at Day 14

Bazett-corrected QTcB interval was evaluated as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.

Time frame:
Baseline (day -1) and day 14
Reported as:
Mean · msec
Mean QTcB Interval (Bazett's Correction Formula, QTcB) - Change From Baseline (Day -1) at Day 14
msecPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day -1 (Predose)438.6 ± 18.07430.7 ± 18.10427.6 ± 13.14436.1 ± 17.61417.3 ± 25.91
Day -1 (0.5 hour)438.1 ± 16.29435.6 ± 21.78429.1 ± 19.47436.5 ± 20.61431.8 ± 20.32
Day -1 (1 hour)442.8 ± 17.55435.3 ± 18.84433.7 ± 18.90439.4 ± 16.23428.8 ± 15.65
Day -1 (1.5 hour)441.3 ± 22.48431.3 ± 20.62427.4 ± 18.56438.5 ± 15.28436.0 ± 16.65
Day -1 (2 hour)437.8 ± 21.87428.3 ± 16.51426.6 ± 17.12430.3 ± 16.49432.1 ± 18.48
Day -1 (2.5 hour)438.1 ± 21.09432.1 ± 22.47422.7 ± 19.67435.9 ± 18.04436.9 ± 21.27
Day -1 (3 hour)436.6 ± 18.42425.7 ± 22.43426.7 ± 16.74435.5 ± 13.93428.4 ± 19.40
Day -1 (4 hour)431.6 ± 18.31423.4 ± 21.21424.6 ± 15.43430.3 ± 14.06431.2 ± 26.00
Day -1 (8 hour)437.0 ± 14.34424.2 ± 17.81425.9 ± 21.39427.1 ± 18.11429.5 ± 27.28
Day -1 (12 hour)438.3 ± 13.91433.4 ± 16.01436.4 ± 9.44434.9 ± 20.98428.8 ± 17.99
Day 14 (Pre dose) Change from Baseline-6.7 ± 14.73-0.3 ± 13.93-6.9 ± 14.02-8.9 ± 25.90-8.5 ± 17.83
Day 14 (0.5 hour) Change from Baseline-5.9 ± 19.59-8.9 ± 17.34-5.5 ± 13.67-3.4 ± 19.47-10.3 ± 17.32
Day 14 (1 hour) Change from Baseline-8.0 ± 16.86-4.6 ± 19.55-8.9 ± 13.33-10.3 ± 23.07-7.5 ± 16.25
Day 14 (1.5 hour) Change from Baseline-6.1 ± 16.420.0 ± 21.00-5.5 ± 10.36-11.1 ± 18.95-8.5 ± 19.32
Day 14 (2 hour) Change from Baseline-5.7 ± 24.18-0.1 ± 15.10-2.9 ± 19.351.9 ± 13.13-7.5 ± 16.37
Day 14 (2.5 hour) Change from Baseline-3.4 ± 23.12-5.7 ± 22.172.2 ± 15.76-1.4 ± 17.37-10.8 ± 16.97
Day 14 (3 hour) Change from Baseline-1.6 ± 13.901.9 ± 20.81-0.4 ± 11.01-6.3 ± 12.49-0.7 ± 14.57
Day 14 (4 hour) Change from Baseline0.4 ± 13.213.3 ± 17.73-4.2 ± 12.68-2.2 ± 16.13-0.1 ± 27.06
Day 14 (8 hour) Change from Baseline-4.4 ± 12.46-0.8 ± 13.485.5 ± 19.09-0.9 ± 14.17-0.2 ± 24.65
Day 14 (12 hour) Change from Baseline0.3 ± 15.112.1 ± 13.19-7.5 ± 16.64-1.2 ± 20.57-0.2 ± 18.66
PrimaryNature and Severity of Adverse Events (AEs) up to Day 21

An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product. Serious Adverse Event (SAE) is an adverse event that at any dose: Results in death, Is life-threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe), Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is considered to be an important medical event.

Time frame:
On or after first drug administration up to end of study (Day 21).
Reported as:
Number · Participants
Nature and Severity of Adverse Events (AEs) up to Day 21
ParticipantsPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Any TEAE137111011
Any Mild TEAE127101011
Any Moderate TEAE11111
Any Severe TEAE00000
Any serious TEAE977511
Any Causally Related TEAE977511
Any Causally Related Serious TEAE110000
Any Life Threatening Serious TEAE00000
Any TEAE of Dehydration00000
Any Death00000
PrimaryWithdrawals Due to AEs up to Day 21

An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product. Serious Adverse Event (SAE) is an adverse event that at any dose: Results in death, Is life-threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe), Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is considered to be an important medical event.

Time frame:
On or after first drug administration up to end of study (Day 21)
Reported as:
Number · Participants
Withdrawals Due to AEs up to Day 21
ParticipantsPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Any TEAE Leading to Discontinuation of Study Drug00000
Any TEAE Leading to Study Discontinuation00000
SecondaryChange in Frequency of Hot Flushes From Baseline (Day -1) at Days 7, 14 as Assessed by Skin Conductance

Sternal skin conductance monitors (the Bahr MonitorTM) and the associated algorithm software were supplied by Simplex Scientific LLC (Middleton, USA). Participants were instructed to push a button on the skin conductance monitor when they sensed a hot flush when fitted with the monitor and then provide details of the hot flush in the continuous hot flush diary. Sternal skin conductance monitors were fitted on Day -1 (24 hours±1 hour prior to the planned study drug administration on Day 1) and remained in place until after the Day 7 24-hour assessments were completed (on Day 8). Refitted around 30 minutes prior to study drug administration on Day 14 and remained in place until after the 24-hour assessments were completed on Day 15.

Time frame:
Baseline (day -1) and days 7, 14
Reported as:
Mean · Hot flushes
Change in Frequency of Hot Flushes From Baseline (Day -1) at Days 7, 14 as Assessed by Skin Conductance
Hot flushesPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline ( Day -1)5.486 ± 7.1488.680 ± 4.7207.787 ± 6.1533.200 ± 4.9455.583 ± 7.242
Change from Day -1 to Day 7-0.857 ± 6.794-3.986 ± 6.487-3.679 ± 4.670-2.197 ± 4.60900.000 ± 6.2450
Change from Day -1 to day 14-0.139 ± 8.0619-2.642 ± 6.0682-2.913 ± 6.42020.600 ± 4.9261-2.908 ± 7.1204
SecondaryChange From Baseline (Week -1) at Weeks 1, 2 in Frequency of Moderate to Severe Hot Flushes as Measured by Twice Daily Paper Diary Throughout Study

Hot flush frequency and hot flush severity were obtained using the Hot Flush paper Diary. Subjects documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.

Time frame:
Baseline (week -1) and Week 1 ,Week 2
Reported as:
Mean · Hot flushes
Change From Baseline (Week -1) at Weeks 1, 2 in Frequency of Moderate to Severe Hot Flushes as Measured by Twice Daily Paper Diary Throughout Study
Hot flushesPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Week -1)10.44 ± 3.86612.70 ± 3.38512.04 ± 3.60610.22 ± 2.9769.90 ± 2.107
Change from Week -1 to Week 1-2.53 ± 3.645-1.91 ± 4.610-5.35 ± 5.153-6.36 ± 3.818-4.49 ± 2.801
Change from Week -1 to Week 2-3.87 ± 4.179-3.07 ± 5.647-7.09 ± 4.915-8.62 ± 3.749-6.54 ± 3.453
SecondaryChange From Baseline (Week -1) at Weeks 1, 2 in Average Daily Severity of Hot Flushes as Measured by Twice Daily Paper Diary

Participants documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.

Time frame:
Baseline (week -1) and weeks 1, Week 2
Reported as:
Mean · Scores on a scale
Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Severity of Hot Flushes as Measured by Twice Daily Paper Diary
Scores on a scalePlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Week -12.32 ± 0.3042.31 ± 0.3192.20 ± 0.2672.16 ± 0.3792.19 ± 0.304
Change from Week -1 to Week 1-0.30 ± 0.358-0.21 ± 0.276-0.23 ± 0.318-0.51 ± 0.542-0.34 ± 0.533
Change from Week -1 to Week 2-0.34 ± 0.383-0.23 ± 0.242-0.36 ± 0.359-0.88 ± 0.656-0.42 ± 0.757
Statistical analysis
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.4641 · Ls means difference: 0.09 · 90% CI -0.12 to 0.30Change from Week -1 to Week 1
  • Placebo vs 100 mg BAY3427080 · LS means difference · p = 0.9894 · Linear mixed-effects model: 0.00 · 90% CI -0.21 to 0.21Change from Week -1 to Week 1
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.0199 · Ls means difference: -0.31 · 90% CI -0.52 to -0.09Change from Week -1 to Week 1
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.3907 · Ls means difference: -0.12 · 90% CI -0.34 to 0.11Change from Week -1 to Week 1
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.5393 · Ls means difference: 0.10 · 90% CI -0.17 to 0.38Change from Week -1 to Week 2
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.7931 · Ls means difference: -0.04 · 90% CI -0.33 to 0.24Change from Week -1 to Week 2
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.0004 · Ls means difference: -0.63 · 90% CI -0.92 to -0.35Change from Week -1 to Week 2
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.3739 · Ls means difference: -0.16 · 90% CI -0.45 to 0.13Change from Week -1 to Week 2
SecondaryChange From Baseline (Week -1) at Weeks 1, 2 in Average Daily Hot Flushes Severity Score as Measured by Twice Daily Paper Diary.

The hot flushes severity score was a composite of the frequency and severity of hot flushes, and was calculated as follows: number of mild hot flushes recorded on Day Y + number of moderate hot flushes recorded on Day Y × 2 + number of severe hot flushes recorded on Day Y × 3. Higher scores mean more severe hot flushes.

Time frame:
Baseline (week -1) and week 1 , 2
Reported as:
Mean · Scores on a scale
Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Hot Flushes Severity Score as Measured by Twice Daily Paper Diary.
Scores on a scalePlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Week -128.06 ± 11.63133.74 ± 8.87532.52 ± 11.20327.87 ± 7.72026.75 ± 5.416
Change from Week -1 to Week 1-6.99 ± 9.673-5.56 ± 10.907-14.48 ± 14.275-17.03 ± 9.996-12.23 ± 7.284
Change from Week -1 to Week 2-10.67 ± 10.542-8.02 ± 13.031-19.19 ± 14.211-22.82 ± 9.505-17.55 ± 8.953
Statistical analysis
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.0900 · Ls means difference: 5.29 · 90% CI 0.16 to 10.42Change from Week -1 to Week 1
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.1487 · Ls means difference: -4.46 · 90% CI -9.55 to 0.63Change from Week -1 to Week 1
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.0012 · Ls means difference: -10.18 · 90% CI -15.20 to -5.15Change from Week -1 to Week 1
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.0548 · Ls means difference: -6.14 · 90% CI -11.37 to -0.90Change from Week -1 to Week 1
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.0522 · Ls means difference: 6.59 · 90% CI 1.03 to 12.15Change from Week -1 to Week 2
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.1326 · Ls means difference: -5.07 · 90% CI -10.61 to 0.48Change from Week -1 to Week 2
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.0004 · Ls means difference: -12.28 · 90% CI -17.73 to -6.83Change from Week -1 to Week 2
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.0253 · Ls means difference: -7.79 · 90% CI -13.47 to -2.11Change from Week -1 to Week 2
SecondaryChange in Frequency From Baseline (Day -1), at Days 7, 14 of Hot Flushes as Measured by Continuous Day Time Diary.

Subjects recorded each hot flush and its severity on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3) in the hot flush paper diary as they occurred during the day and night.

Time frame:
Baseline(day -1) and Day 7, 14
Reported as:
Least squares mean · Hot flushes
Change in Frequency From Baseline (Day -1), at Days 7, 14 of Hot Flushes as Measured by Continuous Day Time Diary.
Hot flushesPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day 7 Change from Day -1-2.8 (-4.5 to -1.0)-1.4 (-3.4 to 0.6)-5.1 (-7.0 to -3.2)-8.3 (-10.2 to -6.4)-5.8 (-7.9 to -3.8)
Day 14 Change from Day -1-3.6 (-4.9 to -2.2)-2.3 (-3.8 to -0.8)-6.0 (-7.5 to -4.5)-8.6 (-10.0 to -7.1)-7.0 (-8.6 to -5.4)
Statistical analysis
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.3796 · Ls means difference: 1.4 · 90% CI -1.2 to 4.0Day 7 Change from Day -1
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.1413 · Ls means difference: -2.3 · 90% CI -4.9 to 0.3Day 7 Change from Day -1
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.0007 · Ls means difference: -5.5 · 90% CI -8.1 to -2.9Day 7 Change from Day -1
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.0624 · Ls means difference: -3.1 · 90% CI -5.8 to -0.4Day 7 Change from Day -1
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.2930 · Ls means difference: 1.3 · 90% CI -0.7 to 3.3Day 14 Change from Day -1
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.0512 · Ls means difference: -2.4 · 90% CI -4.4 to -0.4Day 14 Change from Day -1
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = <0.0001 · Ls means difference: -5.0 · 90% CI -7.0 to -3.0Day 14 Change from Day -1
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.0080 · Ls means difference: -3.4 · 90% CI -5.5 to -1.3Day 14 Change from Day -1
SecondaryChange From Baseline (Week -1) at Weeks 1, 2 in Night-time Awakenings (NTA) Secondary to Hot Flushes as Measured by Paper Diary

The number of NTAs secondary to hot flushes was the sum of the number of moderate and severe night-time hot flushes recorded the following morning (twice-daily hot flush diary) or recorded contemporaneously on the continuous diary.

Time frame:
Baseline (week-1) and weeks 1 , 2
Reported as:
Mean · Night-time Awakenings
Change From Baseline (Week -1) at Weeks 1, 2 in Night-time Awakenings (NTA) Secondary to Hot Flushes as Measured by Paper Diary
Night-time AwakeningsPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Baseline (Week -1)4.51 ± 2.2825.61 ± 1.7855.41 ± 2.3374.74 ± 2.1114.76 ± 1.443
Change from Week -1 to Week 1-0.77 ± 2.066-0.80 ± 2.448-2.52 ± 2.604-2.75 ± 2.335-2.07 ± 1.833
Change from Week -1 to Week 2-1.44 ± 2.128-1.12 ± 2.665-3.00 ± 2.751-3.83 ± 2.008-3.02 ± 2.117
Statistical analysis
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.1482 · Ls means difference: 0.84 · 90% CI -0.12 to 1.80Change from Week -1 to Week 1
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.0734 · Ls means difference: -1.04 · 90% CI -1.99 to -0.09Change from Week -1 to Week 1
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.0022 · Ls means difference: -1.80 · 90% CI -2.74 to -0.86Change from Week -1 to Week 1
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.0660 · Ls means difference: -1.10 · 90% CI -2.08 to -0.12Change from Week -1 to Week 1
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.0593 · Ls means difference: 1.18 · 90% CI 0.15 to 2.20
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.1354 · Ls means difference: -0.93 · 90% CI -1.95 to 0.10Change from Week -1 to Week 2
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.0005 · Ls means difference: -2.20 · 90% CI -3.21 to -1.20Change from Week -1 to Week 2
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.0309 · Ls means difference: -1.38 · 90% CI -2.43 to -0.34Change from Week -1 to Week 2
SecondaryChange From Baseline (Day-1) to Day 1 and Day 7 in Luteinizing Hormone (AUC0-8)

Change in Luteinizing Hormone(LH) AUC from time zero to 8 hours. Pre-dose samples for LH were taken within 30 minutes prior to dose administration.

Time frame:
baseline (day-1) to day 1 and day 7, pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours)
Reported as:
Mean · h*U/L
Change From Baseline (Day-1) to Day 1 and Day 7 in Luteinizing Hormone (AUC0-8)
h*U/LPlacebo50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
Day -1295.4 ± 82.64295.5 ± 85.22290.8 ± 85.83309.5 ± 104.38261.1 ± 65.53
Change from Day -1 to Day 114.4 ± 31.334.7 ± 35.80-10.0 ± 21.90-31.1 ± 38.28-24.6 ± 32.36
Change from Day -1 to Day 712.4 ± 57.4622.9 ± 37.0710.2 ± 20.49-12.1 ± 47.30-4.4 ± 33.43
Statistical analysis
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.3768 · Ls means difference: -9.7 · 90% CI -27.8 to 8.5Change from Day -1 to Day 1
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.0248 · Ls means difference: -25.0 · 90% CI -43.1 to -6.8Change from Day -1 to Day 1
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.0001 · Ls means difference: -43.9 · 90% CI -62.1 to -25.8Change from Day -1 to Day 1
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.0004 · Ls means difference: -42.9 · 90% CI -61.9 to -23.8Change from Day -1 to Day 1
  • Placebo vs 50 mg BAY3427080 · Linear mixed-effects model · p = 0.4819 · Ls means difference: 10.4 · 90% CI -14.2 to 35.1Change from Day -1 to Day 7
  • Placebo vs 100 mg BAY3427080 · Linear mixed-effects model · p = 0.8694 · Ls means difference: -2.4 · 90% CI -27.1 to 22.2Change from Day -1 to Day 7
  • Placebo vs 150 mg BAY3427080 · Linear mixed-effects model · p = 0.1105 · Ls means difference: -23.9 · 90% CI -48.6 to 0.7Change from Day -1 to Day 7
  • Placebo vs 300 mg BAY3427080 · Linear mixed-effects model · p = 0.2390 · Ls means difference: -18.4 · 90% CI -44.2 to 7.4Change from Day -1 to Day 7

Adverse events

Collected over Adverse events data were collected on or after first drug administration up to end of study (Day 21).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Comparator0/18 (0%)0/18 (0%)13/18 (72.2%)
50 mg BAY34270800/15 (0%)0/15 (0%)7/15 (46.7%)
100 mg BAY34270800/15 (0%)0/15 (0%)11/15 (73.3%)
150 mg BAY34270800/15 (0%)0/15 (0%)10/15 (66.7%)
300 mg BAY34270800/13 (0%)0/13 (0%)11/13 (84.6%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlacebo Comparator50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg BAY3427080
SomnolenceNervous system disorders3/185/152/155/159/13
HeadacheNervous system disorders3/180/155/151/156/13
Dermatitis contactSkin and subcutaneous tissue disorders5/182/156/155/152/13
DiarrhoeaGastrointestinal disorders0/181/150/151/153/13
Viral upper respiratory tract infectionInfections and infestations1/180/150/150/153/13
Pelvic painReproductive system and breast disorders2/183/150/150/150/13
Alanine aminotransferase increasedInvestigations0/180/152/150/150/13
DyspepsiaGastrointestinal disorders2/180/150/151/150/13
ConstipationGastrointestinal disorders0/180/151/150/151/13
FlatulenceGastrointestinal disorders0/180/150/150/151/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo Comparator50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg of BAY3427080Total
Mean55.2 ± 4.0855.9 ± 5.5755.3 ± 5.4356.7 ± 4.3753.8 ± 3.8855.4 ± 4.67
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Comparator50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg of BAY3427080Total
Female181515151376
Male000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Comparator50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg of BAY3427080Total
Hispanic or Latino1310810950
Not Hispanic or Latino5575426
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Comparator50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg of BAY3427080Total
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American2442214
White161111131162
More than one race000000
Unknown or Not Reported000000
Weight
Weight(kg)Placebo Comparator50 mg BAY3427080100 mg BAY3427080150 mg BAY3427080300 mg of BAY3427080Total
Mean73.25 ± 10.1170.85 ± 11.8273.47 ± 14.9372.10 ± 7.1072.73 ± 12.0572.48 ± 11.20
08

Study locations

3 sites
  • Avail Clinical Research
    DeLand, Florida 32720, United States
  • QPS/MRA (Miami Clinical Research)
    Miami, Florida 33143, United States
  • ICON Clinical Research Unit
    San Antonio, Texas 78209, United States
09

References and documents

Publications

  • Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Pawsey S. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020 May;27(5):498-505. doi: 10.1097/GME.0000000000001500. PubMed 32068688 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Mar 2017, 7 months.

Results were first posted in Feb 2021, 3 years 10 months after primary completion. A results delay was requested in Oct 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2016
First posted
Aug 12, 2016
StartActual
Aug 1, 2016
Primary completionActual
Mar 28, 2017
CompletionActual
Mar 28, 2017
Results delay requested
Oct 10, 2018
Results first posted
Feb 16, 2021
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02865538
Lead sponsor
Bayer
Collaborators
Nerre Therapeutics Ltd.
Responsible party
Sponsor
First posted
Aug 12, 2016
Start date
Aug 1, 2016
Primary completion
Mar 28, 2017
Completion
Mar 28, 2017
Results posted
Feb 16, 2021
Last update
Feb 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion